BioSpace News Archive

The Medicines Company announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association Scientific Sessions 2019, November 16-18, in Philadelphia.

The Alliance for Safe Biologic Medicines released an abstract from a forthcoming white paper that provides a comprehensive overview of the evolution of the European biosimilars market.

Results of EXTRACT-PE Trial presented at Vascular InterVentional Advances (VIVA) Annual Meeting

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Dr. Eric Mortensen, Chief Medical Officer of CytoSorbents, will leave the company at the end of the year, upon the completion of his current employment contract.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the third quarter of 2019 and provided a corporate update.

Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, today reported its operational and financial results for the third quarter ended September 30, 2019.

Agios Pharmaceuticals, Inc. announced that it is offering to sell, subject to market and other conditions, up to 7.5 million shares of its common stock in an underwritten public offering.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced financial results for the third quarter ended September 30, 2019.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019.

Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced it will report its third quarter 2019 financial results and business progress on Tuesday, November 12, 2019, after the close of the U.S. financial markets.